Differential Expression of Serum TUG1, LINC00657, MiR-9, and MiR-106a in Diabetic Patients With and Without Ischemic Stroke

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2022 Mar 3

PMID 35237654

Authors

Omayma O Abdelaleem

Olfat G Shaker

Mohamed M Mohamed

Tarek I Ahmed

Ahmed F Elkhateeb

Noha K Abdelghaffar

Naglaa A Ahmed

Abeer A Khalefa

Nada F Hemeda

Rania H Mahmoud

Affiliations

Soon will be listed here.

Abstract

Ischemic stroke is one of the serious complications of diabetes. Non-coding RNAs are established as promising biomarkers for diabetes and its complications. The present research investigated the expression profiles of serum TUG1, LINC00657, miR-9, and miR-106a in diabetic patients with and without stroke. A total of 75 diabetic patients without stroke, 77 patients with stroke, and 71 healthy controls were recruited in the current study. The serum expression levels of TUG1, LINC00657, miR-9, and miR-106a were assessed using quantitative real-time polymerase chain reaction assays. We observed significant high expression levels of LINC00657 and miR-9 in the serum of diabetic patients without stroke compared to control participants. At the same time, we found marked increases of serum TUG1, LINC00657, and miR-9 and a marked decrease of serum miR-106a in diabetic patients who had stroke relative to those without stroke. Also, we revealed positive correlations between each of TUG1, LINC00657, and miR-9 and the National Institutes of Health Stroke Scale (NIHSS). However, there was a negative correlation between miR-106a and NIHSS. Finally, we demonstrated a negative correlation between LINC00657 and miR-106a in diabetic patients with stroke. Serum non-coding RNAs, TUG1, LINC00657, miR-9, and miR-106a displayed potential as novel molecular biomarkers for diabetes complicated with stroke, suggesting that they might be new therapeutic targets for the treatment of diabetic patients with stroke.

Citing Articles

Identification and Validation of IFI44 as a Novel Biomarker for Primary Sjögren's Syndrome.

Wei B, Yue Q, Ka Y, Sun C, Zhao Y, Ning X J Inflamm Res. 2024; 17:5723-5740.

PMID: 39219820 PMC: 11366250. DOI: 10.2147/JIR.S477490.

Diabetes and diabetic associative diseases: An overview of epigenetic regulations of TUG1.

Hakami M Saudi J Biol Sci. 2024; 31(5):103976.

PMID: 38510528 PMC: 10951089. DOI: 10.1016/j.sjbs.2024.103976.

The Relevance of Reperfusion Stroke Therapy for miR-9-3p and miR-9-5p Expression in Acute Stroke-A Preliminary Study.

Gendosz de Carrillo D, Kocikowska O, Rak M, Krzan A, Student S, Jedrzejowska-Szypulka H Int J Mol Sci. 2024; 25(5).

PMID: 38474013 PMC: 10931570. DOI: 10.3390/ijms25052766.

Circulating MicroRNAs and Extracellular Vesicle-Derived MicroRNAs as Predictors of Functional Recovery in Ischemic Stroke Patients: A Systematic Review and Meta-Analysis.

Burlacu C, Ciobanu D, Badulescu A, Chelaru V, Mitre A, Capitanescu B Int J Mol Sci. 2023; 24(1).

PMID: 36613694 PMC: 9820088. DOI: 10.3390/ijms24010251.

Taurine-Upregulated Gene 1 Attenuates Cerebral Angiogenesis following Ischemic Stroke in Rats.

Li F, Yu J, Jiang H, Zhang H, Cai Q, Liu Z Biomed Res Int. 2022; 2022:1037525.

PMID: 36330459 PMC: 9626194. DOI: 10.1155/2022/1037525.

References

Hu D, Wang Y, Zhang H, Kong D . Identification of miR-9 as a negative factor of insulin secretion from beta cells. J Physiol Biochem. 2018; 74(2):291-299. DOI: 10.1007/s13105-018-0615-3. View

Duan W, Du L, Jiang X, Wang R, Yan S, Xie Y . Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2016; 7(48):78850-78858. PMC: 5346682. DOI: 10.18632/oncotarget.12880. View

Koutsis G, Siasos G, Spengos K . The emerging role of microRNA in stroke. Curr Top Med Chem. 2013; 13(13):1573-88. DOI: 10.2174/15680266113139990106. View

Wang W, Wang Y, Ma P, Xu T, Shu Y . Taurine‑upregulated gene 1: A vital long non‑coding RNA associated with cancer in humans (Review). Mol Med Rep. 2017; 16(5):6467-6471. DOI: 10.3892/mmr.2017.7472. View

Kitagawa M, Kitagawa K, Kotake Y, Niida H, Ohhata T . Cell cycle regulation by long non-coding RNAs. Cell Mol Life Sci. 2013; 70(24):4785-94. PMC: 3830198. DOI: 10.1007/s00018-013-1423-0. View

Li J, Liu S, Zhou H, Qu L, Yang J . starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2013; 42(Database issue):D92-7. PMC: 3964941. DOI: 10.1093/nar/gkt1248. View

Khoshnam S, Winlow W, Farbood Y, Moghaddam H, Farzaneh M . Emerging Roles of microRNAs in Ischemic Stroke: As Possible Therapeutic Agents. J Stroke. 2017; 19(2):166-187. PMC: 5466283. DOI: 10.5853/jos.2016.01368. View

Mastropasqua R, Toto L, Cipollone F, Santovito D, Carpineto P, Mastropasqua L . Role of microRNAs in the modulation of diabetic retinopathy. Prog Retin Eye Res. 2014; 43:92-107. DOI: 10.1016/j.preteyeres.2014.07.003. View

Ji Q, Ji Y, Peng J, Zhou X, Chen X, Zhao H . Increased Brain-Specific MiR-9 and MiR-124 in the Serum Exosomes of Acute Ischemic Stroke Patients. PLoS One. 2016; 11(9):e0163645. PMC: 5035015. DOI: 10.1371/journal.pone.0163645. View

10.

Wu Y, Xu D, Zhu X, Yang G, Ren M . MiR-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-LOX-meidiated Oxidative/Nitrative Stress. Curr Neurovasc Res. 2017; 14(2):117-124. DOI: 10.2174/1567202614666170404115912. View

11.

Yang D, Yu J, Liu H, Yan X, Hu J, Yu Y . The long non-coding RNA TUG1-miR-9a-5p axis contributes to ischemic injuries by promoting cardiomyocyte apoptosis via targeting KLF5. Cell Death Dis. 2019; 10(12):908. PMC: 6885510. DOI: 10.1038/s41419-019-2138-4. View

12.

Chen C, Cheng G, Yang X, Li C, Shi R, Zhao N . Tanshinol suppresses endothelial cells apoptosis in mice with atherosclerosis via lncRNA TUG1 up-regulating the expression of miR-26a. Am J Transl Res. 2016; 8(7):2981-91. PMC: 4969434. View

13.

Tai L, Huang C, Choo K, Cheong S, Kamarul T . Oxidative Stress Down-Regulates MiR-20b-5p, MiR-106a-5p and E2F1 Expression to Suppress the G1/S Transition of the Cell Cycle in Multipotent Stromal Cells. Int J Med Sci. 2020; 17(4):457-470. PMC: 7053300. DOI: 10.7150/ijms.38832. View

14.

Pinsker J, Shank T, Dassau E, Kerr D . Comment on American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes-2015. Diabetes Care 2015;38(Suppl. 1):S41-S48. Diabetes Care. 2015; 38(10):e174. DOI: 10.2337/dc15-0839. View

15.

Hu B, Cai H, Zheng R, Yang S, Zhou Z, Tu J . Long non-coding RNA 657 suppresses hepatocellular carcinoma cell growth by acting as a molecular sponge of miR-106a-5p to regulate PTEN expression. Int J Biochem Cell Biol. 2017; 92:34-42. DOI: 10.1016/j.biocel.2017.09.008. View

16.

Bao M, Li G, Huang X, Tang L, Dong L, Li J . Long Noncoding RNA LINC00657 Acting as a miR-590-3p Sponge to Facilitate Low Concentration Oxidized Low-Density Lipoprotein-Induced Angiogenesis. Mol Pharmacol. 2018; 93(4):368-375. DOI: 10.1124/mol.117.110650. View

17.

Shaker O, Abdelaleem O, Mahmoud R, Abdelghaffar N, Ahmed T, Said O . Diagnostic and prognostic role of serum miR-20b, miR-17-3p, HOTAIR, and MALAT1 in diabetic retinopathy. IUBMB Life. 2018; 71(3):310-320. DOI: 10.1002/iub.1970. View

18.

Wan W, Wan W, Long Y, Li Q, Jin X, Wan G . Physcion 8-O-β-glucopyranoside exerts protective roles in high glucose-induced diabetic retinopathy via regulating lncRNA NORAD/miR-125/STAT3 signalling. Artif Cells Nanomed Biotechnol. 2020; 48(1):463-472. DOI: 10.1080/21691401.2019.1709861. View

19.

Li Y, Huang D, Zheng L, Cao H, Gao Y, Yang Y . Retracted Article: Long non-coding RNA TUG1 alleviates high glucose induced podocyte inflammation, fibrosis and apoptosis in diabetic nephropathy targeting the miR-27a-3p/E2F3 axis. RSC Adv. 2022; 9(64):37620-37629. PMC: 9075754. DOI: 10.1039/c9ra06136c. View

20.

Zhang L, Cheng H, Yue Y, Li S, Zhang D, He R . TUG1 knockdown ameliorates atherosclerosis via up-regulating the expression of miR-133a target gene FGF1. Cardiovasc Pathol. 2017; 33:6-15. DOI: 10.1016/j.carpath.2017.11.004. View